Preparing an NDA has historically meant months of manual work. Weave’s AI-native platform now handles the data extraction, authoring, content verification, and workflow automation behind that process. This frees regulatory teams to focus on strategic narrative design instead.
Parexel’s regulatory expertise across clinical, non-clinical, and CMC helped shaped how the platform meets NDA-specific demands. Weave has delivered more than 60% faster authoring timelines, without sacrificing quality.
Press release
Weave Bio Launches NDA Workflow Designed in Partnership with Parexel; Extending AI-Native Platform Coverage Across the Full Regulatory Lifecycle
Related news
Press release
Weave Bio Appoints Krates Ng as Chief Technology Officer to Power Enterprise-Scale Regulatory AI
Press release
Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
Press release
Two Former FDA Leaders Join Weave Bio’s Strategic Advisory Board
Press release